

comments, relevant information, or documents regarding the agreements to the Secretary by email at [Secretary@fmc.gov](mailto:Secretary@fmc.gov), or by mail, Federal Maritime Commission, 800 North Capitol Street, Washington, DC 20573. Comments will be most helpful to the Commission if received within 12 days of the date this notice appears in the **Federal Register**, and the Commission requests that comments be submitted within 7 days on agreements that request expedited review. Copies of agreements are available through the Commission's website ([www.fmc.gov](http://www.fmc.gov)) or by contacting the Office of Agreements at (202)-523-5793 or [tradeanalysis@fmc.gov](mailto:tradeanalysis@fmc.gov).

*Agreement No.:* 012355-002.

*Agreement Name:* CMA CGM/SL Gulf Bridge Express Slot Charter Agreement.

*Parties:* CMA CGM S.A.; Maersk A/S dba Sealand.

*Filing Party:* Draughn Arbona, CMA CGM (America) LLC.

*Synopsis:* The Amendment increases the Parties' allocations to reflect larger capacity vessels being brought into the trade and expands the geographic scope of the Agreement to include Brazil. The Parties have requested expedited review.

*Proposed Effective Date:* 11/27/2022.

*Location:* <https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/49>.

*Agreement No.:* 201334-001.

*Agreement Name:* COSCO/ONE/OOCL/YM EMED-USEC Vessel Sharing Agreement.

*Parties:* CMA CGM S.A.; COSCO SHIPPING Lines Co., Ltd; Ocean Network Express Pte. Ltd.; and Orient Overseas Container Line Limited; OOCL (Europe) Limited.

*Filing Party:* Robert Magovern, Cozen O'Connor.

*Synopsis:* The Amendment renames the agreement to the COSCO/ONE/OOCL/CMA CGM EMED-USEC Vessel Sharing Agreement. The Amendment deletes Yang Ming Marine Transport Corp., Yang Ming (UK) Ltd., Yang Ming (Singapore) Pte. Ltd. as parties to the agreement and adds CMA CGM S.A. as a party to the agreement. The Amendment also removes Israel from the scope; revises the agreement to update the BSAs for each of the parties; and updates the duration and resignation section of the agreement.

*Proposed Effective Date:* 11/24/2022.

*Location:* <https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/27479>.

*Agreement No.:* 201393.

*Agreement Name:* CMA CGM/COSCO Vessel Sharing Agreement Mediterranean—U.S. Gulf & East Coast.

*Parties:* CMA CGM S.A.; COSCO SHIPPING Lines Co., Ltd.

*Filing Party:* Draughn Arbona, CMA CGM (America) LLC.

*Synopsis:* The Agreement authorizes CMA CGM and COSCO to share vessels with one another and cooperate on a liner service in the trade between Italy, France, Spain, and Morocco on the one hand and the U.S. Gulf Coast and East Coast on the other hand.

*Proposed Effective Date:* 11/24/2022.

*Location:* <https://www2.fmc.gov/FMC.Agreements.Web/Public/AgreementHistory/69503>.

Dated: October 14, 2022.

**William Cody,**

*Secretary.*

[FR Doc. 2022-22709 Filed 10-18-22; 8:45 am]

**BILLING CODE 6730-02-P**

## FEDERAL MARITIME COMMISSION

[Docket No. 22-27]

### **Globerunners, Incorporated, Complainant v. Hoyer Global (USA), Inc., Respondent; Notice of Filing of Complaint and Assignment**

Served: October 14, 2022.

Notice is given that a complaint has been filed with the Federal Maritime Commission (Commission) by Globerunners, Incorporated, hereinafter "Complainant," against Hoyer Global (USA), Inc., hereinafter "Respondent." Complainant states that it is a non-vessel-operating common carrier that is a corporation organized under the laws of California. Complainant identifies the Respondent as a non-vessel-operating common carrier that is a corporation organized under the laws of Texas.

Complainant alleges that Respondent violated 46 U.S.C. 41102(c) and 41104(a)(14) and 46 CFR 532.5(d)(2)(iv) in its practices and pass-through of charges. The full text of the complaint can be found in the Commission's Electronic Reading Room at <https://www2.fmc.gov/readingroom/proceeding/22-27/>.

This proceeding has been assigned to Office of Administrative Law Judges. The initial decision of the presiding officer in this proceeding shall be issued by October 14, 2023, and the final decision of the Commission shall be issued by April 29, 2024.

**William Cody,**

*Secretary.*

[FR Doc. 2022-22707 Filed 10-18-22; 8:45 am]

**BILLING CODE 6730-02-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2022-N-2107]

### **Pulmonary-Allergy Drugs Advisory Committee; Amendment of Notice**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Pulmonary-Allergy Drugs Advisory Committee. This meeting was announced in the **Federal Register** of September 8, 2022. The amendment is being made to reflect changes in the **DATES, ADDRESSES, and SUPPLEMENTARY INFORMATION** portions of the document. The meeting was rescheduled to allow time for FDA to review new information submitted to the application. There are no other changes.

#### **FOR FURTHER INFORMATION CONTACT:**

Takyiah Stevenson, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 240-402-2507, email: [PADAC@fda.hhs.gov](mailto:PADAC@fda.hhs.gov), or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area). Please call the Information Line for up-to-date information on this meeting.

**SUPPLEMENTARY INFORMATION:** In the **Federal Register** of September 8, 2022, 87 FR 55008, FDA announced that a meeting of the Pulmonary-Allergy Drugs Advisory Committee would be held on October 6, 2022. The following changes are being made.

(1) On page 55008, in the third column, the **DATES** portion of the document is changed to read as follows:

**DATES:** The meeting will be held virtually on November 9, 2022, from 9 a.m. to 5 p.m. Eastern Time.

(2) On page 55008, in the third column, the second paragraph and the first sentence of the third paragraph of the **ADDRESSES** portion of the document are changed to read as follows:

FDA is establishing a docket for public comment on this meeting. The docket number is FDA-2022-N-2107. Please note that late, untimely filed comments will not be considered. The docket will close on November 8, 2022. The <https://www.regulations.gov> electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of November 8, 2022.